David E Heppner (David Heppner)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 38

Top Venues

Journal of medicinal chemistry

ChemMedChem

Communications chemistry

Nature communications

University at Buffalo

Stanford University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University at Buffalo Aug 24 2020

United States

Assistant Professor :: Chemistry

Harvard Medical School Jun 01 2017 - Aug 14 2020

United States

Research Fellow :: Biological Chemistry and Molecular Pharmacology

Dana Farber Cancer Institute Jun 01 2017 - Aug 14 2020

United States

Research Fellow :: Cancer Biology

University of Vermont - May 31 2017

United States

Postdoctoral Fellow :: Pathology and Laboratory Medicine

Education History

Stanford University

United States

PHD :: Chemistry

University of Minnesota

United States

BSC :: Chemistry

Publications

Tyler S Beyett, Jaimin K Rana, Ilse K Schaeffner, David E Heppner, Michael J Eck
Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase. ChemMedChem 19 (12) (2024)
Tyler S Beyett, Jaimin K Rana, Ilse K Schaeffner, David E Heppner, Michael J Eck
Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase. ChemMedChem 19 (12) (2024)
David E Heppner, Simone V Bigi-Botterill, Andrew P Riley, Kelly Chibale, Dennis C Liotta
Structural Biology in Drug Discovery and Development: Call for Papers. Journal of medicinal chemistry 67 (15) (2024)
Florian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D Pham, Ilse K Schaeffner, Brandon T Oligny, Surbhi P Chitnis, Tyler S Beyett, Alexander Rasch, Brian Buckley, Daniel A Urul, Tatiana Shaurova, Earl W May, Erik M Schaefer, Michael J Eck, Pamela A Hershberger, Antti Poso, Stefan A Laufer, David E Heppner
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Communications chemistry 7 (1) (2024)
David E Heppner, Blessing C Ogboo, Daniel A Urul, Earl W May, Erik M Schaefer, Andrew S Murkin, Alexander Titz
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors. Journal of medicinal chemistry (2024)
Florian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D Pham, Ilse K Schaeffner, Brandon T Oligny, Surbhi P Chitnis, Tyler S Beyett, Alexander Rasch, Brian Buckley, Daniel A Urul, Tatiana Shaurova, Earl W May, Erik M Schaefer, Michael J Eck, Pamela A Hershberger, Antti Poso, Stefan A Laufer, David E Heppner
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Communications chemistry 7 (1) (2024)
David E Heppner, Simone V Bigi-Botterill, Andrew P Riley, Kelly Chibale, Dennis C Liotta
Structural Biology in Drug Discovery and Development: Call for Papers. Journal of medicinal chemistry (2024)
Nur P Damayanti, Ricardo A Cordova, Christopher Rupert, Ilaria Delle Fontane, Li Shen, Sabrina Orsi, Angela J Klunk, W Marston Linehan, Kirk A Staschke, Peter C Hollenhorst, David E Heppner, Roberto Pili
TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma. Cancer research 84 (8) (2024)
Florian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D Pham, Ilse K Schaeffner, Brandon T Oligny, Surbhi P Chitnis, Tyler S Beyett, Alexander Rasch, Brian Buckley, Daniel A Urul, Tatiana Shaurova, Earl W May, Erik M Schaefer, Michael J Eck, Pamela A Hershberger, Antti Poso, Stefan A Laufer, David E Heppner
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Communications chemistry 7 (1) (2024)
David E Heppner, Simone V Bigi-Botterill, Andrew P Riley, Kelly Chibale, Dennis C Liotta
Structural Biology in Drug Discovery and Development: Call for Papers. Journal of medicinal chemistry 67 (15) (2024)
Tyler S Beyett, Jaimin K Rana, Ilse K Schaeffner, David E Heppner, Michael J Eck
Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase. ChemMedChem (2024)
Tyler S Beyett, Jaimin K Rana, Ilse K Schaeffner, David E Heppner, Michael J Eck
Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase. ChemMedChem 19 (12) (2024)
Florian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D Pham, Ilse K Schaeffner, Brandon T Oligny, Surbhi P Chitnis, Tyler S Beyett, Alexander Rasch, Brian Buckley, Daniel A Urul, Tatiana Shaurova, Earl W May, Erik M Schaefer, Michael J Eck, Pamela A Hershberger, Antti Poso, Stefan A Laufer, David E Heppner
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Communications chemistry 7 (1) (2024)
David E Heppner, Blessing C Ogboo, Daniel A Urul, Earl W May, Erik M Schaefer, Andrew S Murkin, Alexander Titz
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors. Journal of medicinal chemistry (2024)
Nur P Damayanti, Ricardo A Cordova, Christopher Rupert, Ilaria Delle Fontane, Li Shen, Sabrina Orsi, Angela J Klunk, W Marston Linehan, Kirk A Staschke, Peter C Hollenhorst, David E Heppner, Roberto Pili
TFE3-splicing factor fusions represent functional drivers and druggable targets in translocation renal cell carcinoma. Cancer research (2024)
Florian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D Pham, Ilse K Schaeffner, Brandon T Oligny, Surbhi P Chitnis, Tyler S Beyett, Alexander Rasch, Brian Buckley, Daniel A Urul, Tatiana Shaurova, Earl W May, Erik M Schaefer, Michael J Eck, Pamela A Hershberger, Antti Poso, Stefan A Laufer, David E Heppner
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Communications chemistry 7 (1) (2024)
Nur P Damayanti, Ricardo A Cordova, Christopher Rupert, Ilaria Delle Fontane, Li Shen, Sabrina Orsi, Angela J Klunk, W Marston Linehan, Kirk A Staschke, Peter C Hollenhorst, David E Heppner, Roberto Pili
TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma. Cancer research 84 (8) (2024)
Tyler S Beyett, Jaimin K Rana, Ilse K Schaeffner, David E Heppner, Michael J Eck
Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase. ChemMedChem (2024)
Tyler S Beyett, Jaimin K Rana, Ilse K Schaeffner, David E Heppner, Michael J Eck
Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase. ChemMedChem 19 (12) (2024)
David E Heppner, Simone V Bigi-Botterill, Andrew P Riley, Kelly Chibale, Dennis C Liotta
Structural Biology in Drug Discovery and Development: Call for Papers. Journal of medicinal chemistry (2024)
Kristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, Florian Wittlinger, Stefan A Laufer, Erik M Schaefer, Earl W May, David E Heppner
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors. Journal of medicinal chemistry 67 (1) (2023)
Kristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, Florian Wittlinger, Stefan A Laufer, Erik M Schaefer, Earl W May, David E Heppner
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors. Journal of medicinal chemistry 67 (1) (2023)
Kristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, Florian Wittlinger, Stefan A Laufer, Erik M Schaefer, Earl W May, David E Heppner
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors. Journal of medicinal chemistry (2023)
Kristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, Florian Wittlinger, Stefan A Laufer, Erik M Schaefer, Earl W May, David E Heppner
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors. Journal of medicinal chemistry 67 (1) (2023)
David E Heppner, Florian Wittlinger, Blessing Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin Pham, Ilse Schaeffner, Brandon T Oligny, Surbhi Chitnis, Tyler Beyett, Alexander Rasch, Brian Buckley, Daniel Urul, Tatiana Shaurova, Earl May, Erik Schaefer, Michael J Eck, Pamela Hershberger, Antti Poso, Stefan A Laufer
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Research square (2023)
Ciric To, Tyler S Beyett, Jaebong Jang, William W Feng, Magda Bahcall, Heidi M Haikala, Bo H Shin, David E Heppner, Jaimin K Rana, Brittaney A Leeper, Kara M Soroko, Michael J Poitras, Prafulla C Gokhale, Yoshihisa Kobayashi, Kamal Wahid, Kari J Kurppa, Thomas W Gero, Michael D Cameron, Atsuko Ogino, Mierzhati Mushajiang, Chunxiao Xu, Yanxi Zhang, David A Scott, Michael J Eck, Nathanael S Gray, Pasi A Janne
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nature cancer 3 (4) (2022)
Tyler S Beyett, Ciric To, David E Heppner, Jaimin K Rana, Anna M Schmoker, Jaebong Jang, Dries J H De Clercq, Gabriel Gomez, David A Scott, Nathanael S Gray, Pasi A Janne, Michael J Eck
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nature communications 13 (1) (2022)
Yoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen, Navin R Mahadevan, Joao V Alessi, Yin Pun Hung, Arrien A Bertram, David E Heppner, Maurício Fernando Silva Almeida Ribeiro, Karina P Sacardo, Rodrigo Saddi, Mariana Petaccia de Macedo, Rafael B Blasco, Jiaqi Li, Kari J Kurppa, Tom Nguyen, Emma Voligny, Guruprasad Ananda, Roberto Chiarle, Artur Katz, Michael Y Tolstorukov, Lynette M Sholl, Pasi A Janne
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. Nature communications 13 (1) (2022)
Florian Wittlinger, David E Heppner, Ciric To, Marcel Günther, Bo Hee Shin, Jaimin K Rana, Anna M Schmoker, Tyler S Beyett, Lena Marie Berger, Benedict-Tilmann Berger, Nicolas Bauer, James D Vasta, Cesear R Corona, Matthew B Robers, Stefan Knapp, Pasi A Jänne, Michael J Eck, Stefan A Laufer
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites. Journal of medicinal chemistry (2021)
Christopher M Dustin, Aida Habibovic, Milena Hristova, Caspar Schiffers, Carolyn R Morris, Miao-Chong Joy Lin, Robert A Bauer, David E Heppner, Nirav Daphtary, Minara Aliyeva, Albert van der Vliet
Oxidation-Dependent Activation of Src Kinase Mediates Epithelial IL-33 Production and Signaling during Acute Airway Allergen Challenge. Journal of immunology (Baltimore, Md. : 1950) (2021)
David E Heppner, Michael J Eck
A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer. Protein science : a publication of the Protein Society 30 (8) (2021)
Stephen M Jones, David E Heppner, Kenny P Vu, Daniel J Kosman, Edward I Solomon
Rapid Decay of the Native Intermediate in the Metallooxidase Fet3p Enables Controlled FeII Oxidation for Efficient Metabolism. Journal of the American Chemical Society 142 (22) (2020)
David E Heppner, Marcel Günther, Florian Wittlinger, Stefan A Laufer, Michael J Eck
Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. Journal of medicinal chemistry 63 (8) (2020)
David E Heppner, Tyler S Beyett, Michael J Eck
A driving test for oncogenic mutations. The Journal of biological chemistry 294 (24) (2020)
Andrew C Little, Milena Hristova, Loes van Lith, Caspar Schiffers, Christopher M Dustin, Aida Habibovic, Karamatullah Danyal, David E Heppner, Miao-Chong J Lin, Jos van der Velden, Yvonne M Janssen-Heininger, Albert van der Vliet
Dysregulated Redox Regulation Contributes to Nuclear EGFR Localization and Pathogenicity in Lung Cancer. Scientific reports 9 (1) (2019)
Ciric To, Jaebong Jang, Ting Chen, Eunyoung Park, Mierzhati Mushajiang, Dries J H De Clercq, Man Xu, Stephen Wang, Michael D Cameron, David E Heppner, Bo Hee Shin, Thomas W Gero, Annan Yang, Suzanne E Dahlberg, Kwok-Kin Wong, Michael J Eck, Nathanael S Gray, Pasi A Jänne
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer discovery 9 (7) (2019)
Albert van der Vliet, Karamatullah Danyal, David E Heppner
Dual oxidase: a novel therapeutic target in allergic disease. British journal of pharmacology 175 (9) (2018)
David E Heppner, Christopher M Dustin, Chenyi Liao, Milena Hristova, Carmen Veith, Andrew C Little, Bethany A Ahlers, Sheryl L White, Bin Deng, Ying-Wai Lam, Jianing Li, Albert van der Vliet
Direct cysteine sulfenylation drives activation of the Src kinase. Nature communications 9 (1) (2018)

David E Heppner.css-eqlu8i{font-size:small;padding-left:4px;} (David Heppner)

Publication Activity (10 Years)

Top Topics

Top Venues

David E Heppner (David Heppner)